Category: Federal Forum Posters
Purpose: Direct oral anticoagulants (DOACS) are preferred over warfarin for the treatment of venous thromboembolism (VTE) as well as atrial fibrillation (AF). The efficacy and safety of fixed-dose regimen of DOACs remains unclear in the obese patient population. This retrospective single-center cohort study seeks to further investigate the clinical outcomes of venous thromboembolism (VTE) recurrence, stroke, all-cause death, and major bleeding in the morbidly obese veteran population on DOACS as compared to warfarin.
Methods: This study will be submitted to the Institutional Review Board for approval. A retrospective chart review will be conducted for morbidly obese veteran patients with a weight greater than 120 kg or BMI greater than 40 kg/m2 who were prescribed direct oral anticoagulants (DOACS) or warfarin between January 1st, 2015 to May 31st, 2018. Data will be extracted from the computerized patient record system (CPRS) and a data warehouse. All data will be reported without patient identifiers and patient confidentiality will be maintained. Patients will be included if they were on anticoagulation for at least 90 days for an indication of atrial fibrillation, atrial flutter, deep vein thrombosis (DVT), pulmonary embolism (PE), venous thromboembolism (VTE), or recurrent PE/DVT. The primary efficacy outcome was composite incidence of stroke/transient ischemic attack, VTE, and all-cause mortality. The primary safety outcome was the incidence of major bleeding.
Results: not applicable
Conclusion: not applicable
Morgan Lebrecht– Pharmacy Resident, Salem VA Medical Center, Troy, NY